Research reported at the 1999 European Society for ...



For Immediate ReleaseThe Society of Thermal Medicine Highlights Hyperthermia European Adjuvant Trial (HEAT) on Pancreatic Cancer at its 19th Annual Conference Portland , OR April 14, 2012 - The Society of Thermal Medicine (STM) highlighted initiation of an important Phase III clinical study, hyperthermia in combination with chemotherapy for the treatment of pancreatic cancer patients, during its 29th Annual Conference, which was held recently in Portland, OR. The randomized, multicenter, Phase III study, the Hyperthermia European Adjuvant Trial (HEAT), sponsored by the Munich Groshadern University Medical School (UMS) and the European Society for Hyperthermic Oncology, compares hyperthermia with chemotherapy (gemcitabine plus cisplatin) to chemotherapy (gemcitabine) alone. Patients are randomized following standard surgical resection of the tumor. The study is open for enrollment of 350 patients and has already enrolled the first three patients. Patient enrollment is expected to proceed quickly. The principal investigators are Rolf D. Issels, MD PhD, and Katharina Lechner, MD, from the Munich Grosshadern UMS, Munich, Germany.The following clinical sites will initially participate in the clinical study: Munich Grosshadern UMS, Munich, Klinik Bad Trissl, Oberaudorf, Red Cross Hospital, Munich, UMS Düsseldorf, UMS Erlangen and UMS Tübingen, all Germany. These sites all utilize the BSD-2000 Hyperthermia System.Pancreatic cancer is one of the deadliest and most difficult to treat cancers and is the fourth leading cause of cancer-related death in the U.S. and throughout the world. There will be an estimated 44,000 Americans and 60,000 Europeans diagnosed with pancreatic cancer during 2012. The median survival is approximately 6 months for patients with metastatic disease and 10 months for patients with locally advanced disease. Median survival after 5 years is <5 % of all patients. Advanced pancreatic cancer patients currently have few treatment options. About the Society for Thermal Medicine The Society for Thermal Medicine (STM) was founded in 1986 as a professional society to significantly improve treatment outcomes by advancing the science, development and application of thermal therapy. STM is a premier, international scientific forum for fostering interaction and innovation in the study of biological, physical and medical applications of thermal therapy for cancer and other diseases. STM promotes rapid dissemination of exciting scientific breakthroughs in thermal medicine in order to expedite the translation of both basic and applied research to the clinic for the immediate benefit of patients. STM also sponsors high quality forums for education of medical professionals in the practice of thermal medicine. ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download